CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal interstitial lung disease (ILD); other ILDs have a progressive, fibrotic phenotype (PF-ILD). Antifibrotic agents can slow but not stop disease progression in patients with IPF or PF-ILD. c-Jun N-terminal kinases (JNKs...

Descripción completa

Detalles Bibliográficos
Autores principales: Popmihajlov, Zoran, Sutherland, Donna J, Horan, Gerald S, Ghosh, Atalanta, Lynch, David A, Noble, Paul W, Richeldi, Luca, Reiss, Theodore F, Greenberg, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783810/
https://www.ncbi.nlm.nih.gov/pubmed/35058236
http://dx.doi.org/10.1136/bmjresp-2021-001060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783810/
https://www.ncbi.nlm.nih.gov/pubmed/35058236
http://dx.doi.org/10.1136/bmjresp-2021-001060

Ejemplares similares